Krystal Moya

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 194 citations · Full text

Medicine, Oncology, Pharmacology +10

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers

Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski et al. · Journal of Medicinal Chemistry · 2022 · 151 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

John M. Ketcham, Jacob R. Haling, Shilpi Khare et al. · Journal of Medicinal Chemistry · 2022 · 94 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos et al. · Molecular Cancer Therapeutics · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacology +14

Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors

Christopher R. Smith, Svitlana Kulyk, J.D. Lawson et al. · Cancer Research · 2021 · 14 citations

Medicine, Oncology, Pharmacology +15